311C90, a new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose-range finding study

Neurology
W H VisserM Ferrari

Abstract

311C90 is a novel, centrally and peripherally, acting 5-hydroxytryptamine1D receptor agonist. We investigated the efficacy and safety of 1, 5, and 25 mg of oral 311C90 in the acute treatment of migraine in a randomized, double-blind, placebo-controlled, parallel-group clinical trial involving 84 patients. The proportion of patients in whom the headache improved within 2 hours from moderate or severe to mild or no pain (primary efficacy measure) was 15% for placebo-treated patients and 27% (1 mg), 62% (5 mg), and 81% (25 mg) for patients treated with 311C90. Treatment differences compared with placebo were 12% (95% CI - 12, 37; p = 0.460) for 1 mg 311C90, 47% (CI 21, 73; p < 0.005) for 5 mg 311C90, and 66% (CI 43,89; p < 0.001) for 25 mg 311C90. Photophobia and nausea also showed improvement after 311C90. Adverse events were generally mild and transient in all treatment groups. There were no clinically significant changes in ECG recordings, blood pressure, or laboratory tests. Oral 311C90 (5 and 25 mg) is highly effective and well tolerated in the acute treatment of migraine. The response rates and treatment differences compared with placebo in this study suggest possible superiority over existing antimigraine therapies. This ne...Continue Reading

Citations

Oct 9, 2002·Pharmazie in unserer Zeit·Hans-Christoph Diener
Aug 7, 2002·Current Treatment Options in Neurology·Sheena K. Aurora, John Dempsey
Jun 28, 2000·Progress in Neurobiology·P J Goadsby
Oct 12, 2001·Cephalalgia : an International Journal of Headache·B Gomez-MancillaD E Blunt
Oct 18, 2002·Cephalalgia : an International Journal of Headache·M D FerrariR B Lipton
Sep 3, 2003·Cephalalgia : an International Journal of Headache·U ReuterUNKNOWN GSK Headache Masters Program
Jan 22, 2005·Cephalalgia : an International Journal of Headache·E LoderD Biondi
Jul 7, 2000·Journal of Clinical Pharmacology·D Deleu, Y Hanssens
May 25, 2002·CNS Drugs·Seymour Diamond, Richard Wenzel
Nov 5, 2005·CNS Drugs·Lisa K Mannix, Julia A Files
Jul 1, 1999·Canadian Family Physician Médecin De Famille Canadien
Nov 22, 2007·Expert Opinion on Drug Metabolism & Toxicology·B Lee Peterlin, Alan M Rapoport
Jul 5, 2005·Expert Opinion on Investigational Drugs·P E Rolan, G R Martin
Dec 5, 2002·Current Medical Research and Opinion·P J Goadsby, C J Boes
Apr 4, 2009·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Ayelet AvitalRoni Shiloh
Apr 12, 2001·Arquivos de neuro-psiquiatria·A V KrymchantowskiL A Alves
Aug 2, 2000·Arquivos de neuro-psiquiatria·A V Krymchantowski
Aug 24, 1999·Pharmacotherapy·K W WeitzelJ V Goode
May 11, 1999·Cephalalgia : an International Journal of Headache·A V KrymchantowskiD Fernandes
May 1, 1997·Cephalalgia : an International Journal of Headache·P J Goadsby, Y E Knight
Feb 11, 2000·Cephalalgia : an International Journal of Headache·K I RoonJ G van Dijk
May 23, 2014·The Cochrane Database of Systematic Reviews·Sarah BirdR Andrew Moore
Jun 27, 2002·Expert Opinion on Pharmacotherapy·Andrew J Dowson, Bruce Charlesworth
May 21, 2004·The Journal of Pharmacology and Experimental Therapeutics·Baojun GuPaul C Dolber
Apr 22, 1999·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·C DahlofK B Klein
Dec 2, 1998·British Journal of Clinical Pharmacology·E J SeaberJ H Jonkman
Dec 17, 1997·Cephalalgia : an International Journal of Headache·J Schoenen, J Sawyer

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.